Back to Search
Start Over
Matrix Metalloproteinase 3 Predicts Therapeutic Response in Inflammatory Bowel Disease Patients Treated With Infliximab.
- Source :
-
Inflammatory bowel diseases [Inflamm Bowel Dis] 2020 Apr 11; Vol. 26 (5), pp. 756-763. - Publication Year :
- 2020
-
Abstract
- Background and Aims: Inflammatory bowel diseases (IBDs) are treated with anti-TNF agents. Strategies to monitor response to therapy may improve clinical control of the disease and reduce economical costs. Previous evidence suggests cleavage of infliximab (IFX) by Matrix Metalloproteinase 3 (MMP3) as a mechanism leading to loss of response. Our study aimed to evaluate if MMP3 serum levels could be considered an early marker of anti-TNF nonresponse and to analyze the correlation with other biochemical markers of treatment failure such as IFX trough levels and anti-IFX antibodies, inflammatory markers, and albumin levels.<br />Methods: Retrospectively, 73 IBD patients who had received IFX for at least 1 year were enrolled: 35 patients were responders and 38 were nonresponders at 52 weeks. Clinical and biochemical data (Harvey-Bradshaw index [HBI], Mayo score, body mass index [BMI], C-reactive protein [CRP], fecal calprotectin and albumin levels), MMP3 serum levels, and drug monitoring were assessed at baseline, postinduction, and 52 weeks.<br />Results: The MMP3 levels were similar at baseline (19.83 vs 17.92 ng/mL), but at postinduction, patients who failed to respond at 1 year had significantly higher levels than patients who responded (26.09 vs 8.68 ng/mL, P < 0.001); the difference was confirmed at week 52 (29.56 vs 11.48 ng/mL, P < 0.001). The MMP3 levels tended to be higher in patients without antidrug antibodies than in patients with antidrug antibodies at postinduction and 52 weeks.<br />Conclusions: The MMP3 serum determination may represent an early marker of response to infliximab.<br /> (© 2019 Crohn’s & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Subjects :
- Adolescent
Adult
Albumins analysis
Biomarkers blood
C-Reactive Protein analysis
Colitis, Ulcerative blood
Crohn Disease blood
Drug Monitoring methods
Feces chemistry
Female
Humans
Induction Chemotherapy
Leukocyte L1 Antigen Complex analysis
Male
Middle Aged
Predictive Value of Tests
Retrospective Studies
Treatment Failure
Young Adult
Colitis, Ulcerative drug therapy
Crohn Disease drug therapy
Gastrointestinal Agents therapeutic use
Infliximab therapeutic use
Matrix Metalloproteinase 3 blood
Subjects
Details
- Language :
- English
- ISSN :
- 1536-4844
- Volume :
- 26
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Inflammatory bowel diseases
- Publication Type :
- Academic Journal
- Accession number :
- 31504536
- Full Text :
- https://doi.org/10.1093/ibd/izz195